摘要
目的探讨噻托溴铵粉吸入剂联合沙美特罗替卡松粉吸入剂对慢性阻塞性肺疾病(COPD)患者炎性因子水平的影响。方法选取2018年5月至2019年5月期间收治的200例COPD患者为研究对象,采用随机数表法将其分为对照组(n=100)及观察组(n=100)。对照组采用沙美特罗替卡松粉吸入剂治疗,观察组在对照组的基础上联合使用噻托溴铵粉吸入剂治疗。治疗6个月后,比较2组肺功能[一秒钟用力呼气容积(FEV1)、最大肺活量(FVC),及其比值(FEV1/FVC)]和血清炎性因子[白细胞介素-8(IL-8)、白细胞介素-10(IL-10)和肿瘤坏死因子-α(TNF-α)]表达水平,并评估治疗效果。结果治疗6个月后,2组FEV1、FVC及FEV1/FVC均高于治疗前,且观察组高于对照组(P<0.05);2组IL-10水平高于治疗前,且观察组高于对照组(P<0.05);2组IL-8及TNF-α水平均低于治疗前,且观察组低于对照组(P<0.05);观察组临床有效率高于对照组(90.00%vs 71.00%,P<0.05)。结论噻托溴铵粉吸入剂联合沙美特罗替卡松粉吸入剂可有效改善COPD患者肺功能及血清炎性因子水平,临床疗效优于单独使用沙美特罗替卡松粉吸入剂治疗。
AIM To investigate the effects of tiotropium bromide powder for inhalation combined with salmeterol xinafoate and fluticasone propionate powder for inhalation on inflammatory factors in chronic obstructive pulmonary disease(COPD)patients.METHODS Totally 200 COPD patients admitted to our hospital were selected as the study objects from May 2018 to May 2019.They were divided into control group(n=100)and observation group(n=100)by random number table method.The control group was treated with salmeterol xinafoate and fluticasone propionate powder for inhalation,and the observation group was treated with tiotropium bromide powder for inhalation on the basis of the control group.After 6 months of treatment,the lung function[forced expiratory volume in one second(FEV1),forced vital capacity(FVC),and FEV1/FVC]and the expression of serum inflam-matory factors[interleukin-8(IL-8),interleukin-10(IL-10)and tumor necrosis factor alpha(TNF-α)]were compared between 2 groups,and the therapeutic effect was evaluated.RESULTS After 6 months of treatment,FEV1,FVC and FEV1/FVC in 2 groups were higher than those before treatment,and the observation group were higher than the control group(P<0.05).After treatment,the level of IL-10 in 2 groups was higher than before treatment,and the observation group was higher than the control group(P<0.05).After treatment,the levels of IL-8 and TNF-αin 2 groups were lower than those before treatment,and those in the observation group were lower than those in the control group(P<0.05).The clinical efficiency of the observation group was higher than that in the control group(90.00%vs 71.00%,P<0.05).CONCLUSION Tiotropium bromide powder for inhalation combined with salmeterol xinafoate and fluticasone propionate powder for inhalation can effectively improve the lung function and serum inflammatory factors level of COPD patients,and the clinical effect is better than that of salmeterol xinafoate and fluticasone propionate powder for inhalation alone.
作者
史东明
赵德军
王霞
徐浩锋
SHI Dongming;ZHAO Dejun;WANG Xia;XU Haofeng(Department of Pharmacy,The First People’s Hospital,Fuyang District,Hangzhou City,Zhejiang Province,Hangzhou 311400,China;Department of Respiratory,The First People’s Hospital,Fuyang District,Hangzhou City,Zhejiang Province,Hangzhou 311400,China)
出处
《中国临床药学杂志》
CAS
2020年第6期410-414,共5页
Chinese Journal of Clinical Pharmacy
基金
浙江省卫生科技计划项目(编号2020372192)。
关键词
慢性阻塞性肺疾病
沙美特罗替卡松
噻托溴铵
炎性因子
chronic obstructive pulmonary disease
salmeterol/fluticasone
tiotropium
inflammatory factor
